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AbsTrACT
Objective To explore the additive effect of 
neurodegenerative diseases, measured by atrophy, on 
neurocognitive function in Asian dementia-free elderly with 
cerebrovascular disease (CeVD).
Methods The present study employed a cross-sectional 
design and was conducted between 2010 and 2015 
among community-dwelling elderly participants recruited 
into the study. Eligible participants were evaluated with an 
extensive neuropsychological battery and neuroimaging. 
The weighted CeVD burden scale comprising markers 
of both small- and large-vessel diseases was applied, 
with a score of ≥2, indicating significant CeVD burden. 
Cortical atrophy (CA) and medial temporal atrophy (MTA) 
were graded using the global cortical atrophy scale and 
Schelten’s scale, respectively. Global and domain-specific 
(attention, executive function, language, visuomotor speed, 
visuoconstruction, visual memory, and verbal memory) 
neurocognitive performance was measured using a locally 
validated neuropsychological battery (Vascular Dementia 
Battery, VDB).
results A total of 819 dementia-free participants were 
included in the analysis. Among none-mild CeVD subjects, 
there was no significant difference in the global cognitive 
performance across atrophy groups (no atrophy, CA, and 
CA+MTA). However, in moderate-severe CeVD subjects, 
CA+MTA showed significantly worse global cognitive 
performance compared with those with CA alone (mean 
difference=−0.35, 95% CI −0.60 to −0.11, p=0.002) and 
those without atrophy (mean difference=−0.46, 95% CI 
−0.74 to −0.19, p<0.001, p<0.001). In domain-specific 
cognitive performance, subjects with CA+MTA performed 
worse than other groups in visual memory (p=0.005), 
executive function (p=0.001) and visuomotor speed 
(p<0.001) in moderate-severe CeVD but not in none-mild 
CeVD.
Conclusions and relevance Atrophy and moderate-
severe CeVD burden showed an additive effect on 
global and domain-specific cognitive performance. This 
study highlights the importance of investigating the 
mechanisms of clinico-pathological interactions between 
neurodegenerative processes and vascular damage, 
particularly in the pre-dementia stage.
InTrOduCTIOn
Brain atrophy is a neuroimaging marker of 
neurodegeneration caused by Alzheimer’s 
disease (AD),1 2 whereas cerebrovascular 
disease (CeVD) is considered the main 
contributor to vascular-related cognitive 
impairment (CI). The independent effect 
of atrophy and CeVD on cognition has been 
found in dementia patients,3 suggesting 
that atrophy and CeVD may contribute via 
differing mechanisms to CI.
Although atrophy is not commonly consid-
ered a typical CeVD marker, its association 
with brain CeVD severity is acknowledged.4–6 
Atrophy and CeVD have been widely reported 
among elderly dementia patients, empha-
sising the overlapping pathology of AD and 
vascular dementia.7–9 In autopsy studies, the 
presence of CeVD, such as microinfarcts, 
shows an additive effect to AD pathology in 
increasing the odds of developing dementia 
and CI.10 Moreover, a recent imaging study on 
patients attending clinics in tertiary centres 
has shown that higher amyloid burden 
contributes to further deterioration in cogni-
tion, interactively with more severe CeVD.11 
However, the additive effect of atrophy and 
CeVD on cognitive function has been mainly 
focused on dementia populations and has not 
been examined in a dementia-free elderly 
cohort.
A novel approach was recently developed 
for quantifying global CeVD burden that 
includes both small- and large-vessel disease. 
The simplified 4-point global CeVD burden 
scale was constructed and validated, and a 
threshold effect of global CeVD burden on 
cognition was found.12 13 Hence, the present 
study sought to explore in an Asian demen-
tia-free elderly population if there was an 
additive joint effect of atrophy above and 
beyond CeVD on cognition.
MeThOds
study population
The Epidemiology of Dementia In Singa-
pore (EDIS) study drew participants from the 
Singapore Epidemiology of Eye Disease study, 
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a multi-ethnic population-based study. An age-stratified 
(40–85 years) random sampling method was used to estab-
lish the study population with adequate representation of 
each ethnic group, that is, Chinese (Singapore Chinese 
Eye Study), Malay (Singapore Malay Eye Study) and 
Indian (Singapore Indian Eye Study). In the first phase of 
the EDIS study, participants aged ≥60 years (n=3800) were 
screened using the Abbreviated Mental Test and a self-re-
port of progressive forgetfulness. Screen-positive subjects 
(n=1598) were invited to take part in the second phase of 
this study, which included a clinical evaluation, an exten-
sive, locally validated neuropsychological test battery 
(the vascular dementia battery, VDB)14 15 and brain MRI. 
Out of these 1598 participants, 957 agreed to partici-
pate in phase II and hence were included in the present 
study, among whom 911 were dementia-free elderly. The 
study recruitment period was from 8 December 2010 to 
24 July 2015. Subjects who refused to participate in phase 
II were older, had lower education and socioeconomic 
status, higher blood pressures and lower cholesterol 
levels.16 Details of the EDIS study methodology have been 
described elsewhere.17 Ethical approval was obtained 
from the National Healthcare Group Domain-Specific 
Review Board. Written informed consent was obtained in 
the preferred language of the participants.
Vascular risk profile
A vascular risk profile was recorded for all study partic-
ipants, which included the following: (1) hyperten-
sion, defined as a previous diagnosis of hypertension, 
the use of antihypertensive medication, or a systolic 
blood pressure ≥140 mmHg and/or diastolic blood 
pressure ≥90 mmHg on clinical assessment; (2) hyper-
lipidemia, defined as a previous diagnosis of hyperlipi-
demia, the use of lipid-lowering medication or total 
cholesterol levels≥4.14 mmol/L; (3) diabetes mellitus, 
defined as a previous diagnosis of diabetes mellitus, the 
use of glucose-lowering medication or glycated haemo-
globin ≥6.5%; (4) ischaemic heart disease, defined as a 
previous diagnosis of the following—myocardial infarc-
tion, congestive heart failure, atrial fibrillation, coro-
nary angioplasty or stenting; (5) self-reported history of 
smoking; and (6) documented history of stroke.
neuroimaging protocol
MRI scans were performed on a 3T Siemens Magnetom 
Trio Tim scanner, using a 32-channel head coil. Several 
MRI brain sequences were performed to allow morpho-
logical and microstructure assessments, including 
T1-weighted, fluid attenuated inversion recovery, 
T2-weighted and susceptibility-weighted imaging.
MRI markers of CeVD were graded following the previ-
ously described procedures:12 13
1. Cortical infarcts were defined as focal lesions involv-
ing cortical grey matter, signal following cerebrospinal 
fluid intensity, hyperintense rim on fluid-attenuated 
inversion recovery images and tissue loss of variable 
magnitude, with prominent adjacent sulci and ipsilat-
eral ventricular enlargement.18
2. Intracranial stenosis (ICS) was defined as narrowing 
exceeding 50% of the luminal diameter in any of the 
intracranial vessels assessed on three-dimensional 
time-of-flight magnetic resonance angiography. The 
images were first visually assessed on the reconstructed 
images, and the final decision on stenosis (>50%) was 
made on the source images.
3. Lacunes were defined as lesions, 3–15 mm in diameter, 
with a low signal on T1-weighted image and fluid atten-
uated inversion recovery, a high signal on T2-weighted 
image and a hyperintense rim with a centre following 
cerebrospinal fluid intensity on fluid-attenuated inver-
sion recovery.19
4. White matter hyperintensities (WMH) were graded us-
ing the Modified Fazekas Scale.20
5. Cerebral microbleeds were defined on suscepti-
bility-weighted imaging sequences using the Brain 
Observer Microbleed Scale.21
MRI markers of CeVD were transformed into binary 
variables and recorded as the presence/absence of 
multiple lacunar infarcts, multiple microbleeds, cortical 
infarcts, ICS and moderate-severe severity of WMH on the 
Fazekas scale. The weighted CeVD burden scale,12 which 
was established based on the strength of independent 
association between CeVD markers and global neurocog-
nitive performance, was applied in the present study to 
indicate global CeVD burden severity (none-very mild 
[0], mild [1], moderate [2] and severe [3]). Significant 
CeVD was defined by a score of 2 and above; hence, two 
CeVD groups were obtained: (1) none-mild; (2) moder-
ate-severe (refer to online supplementary material for 
details of the scale).
Cortical atrophy (CA) was graded on the Global 
Cortical Atrophy Scale,22 and medial temporal atrophy 
(MTA) was graded  on the Scheltens Scale.23 The pres-
ence of significant CA or MTA was defined by a score 
of ≥3 on either scale.
Subsequently, three atrophy groups were classified 
according to CA and MTA grading: (1) no atrophy, as 
defined by the absence of significant atrophy (CA and 
MTA); (2) CA, as defined by the presence of significant 
CA and the absence of MTA and (3) CA+MTA, as defined 
by the presence of significant CA and MTA.
neuropsychological assessment
The VDB measures the following domains: (1) attention 
(digit span test, visual span test and auditory detection 
test); (2) language (15-item modified Boston Naming 
Test and category fluency); (3) visuoconstruction (visual 
reproduction subtest of the Weschler Memory Scale-Re-
vised copy task, clock drawing and the block design 
subtest of the Weschler Adult Intelligence Scale-Re-
vised); (4) visuomotor speed (digit cancellation, maze 
and symbol digit modalities); (5) verbal memory (word 
list recall and story recall); (6) visual memory (picture 
recall and the visual reproduction subtest of the Weschler 
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Memory Scale-Revised) and (7) executive function 
(frontal assessment battery). All individual tests on the 
VDB are widely used tests and are adapted to the local 
population.24
Cognitive impairment status
Weekly research consensus meetings were held among 
clinicians, psychologists and research personnel. Details 
from the clinical assessment, blood investigations, 
neuropsychological testing and MRI scans were reviewed. 
The diagnosis of no cognitive impairment was given to 
participants who had neither objective CI on formal 
neuropsychological tests nor functional loss. The diag-
nosis of cognitive impairment-no dementia (CIND) was 
given to participants who had impairment on at least one 
cognitive domain on the VDB without functional loss, 
and therefore did not meet the criteria for dementia. 
CIND was further classified into CIND-mild (impairment 
in one or two domains on the VDB) and CIND-moderate 
(impairment in three or more domains on the VDB). 
Details of diagnostic criteria have been described else-
where.16 24
statistical analysis
Raw scores for all individual cognitive tests on the VDB 
were transformed to standardised z-scores using the 
means and SDs of the entire sample. The z-score for 
each domain was created by averaging the z-scores of 
individual tests and standardised using the means and 
SDs of the entire sample. To obtain the global cognitive 
z-score for each patient, the domain z-scores were aver-
aged and standardised using the means and SDs of the 
entire sample.
The additive effect of CeVD and atrophy was measured 
by comparing across three atrophy groups (no atrophy, 
CA, and CA+MTA), stratified by CeVD burden severity. 
Sensitivity analysis was performed by modelling cases with 
incomplete MRI investigation. In model 1, any individual 
who had missing values for CeVD and atrophy severity 
was assigned to ‘moderate-severe CeVD and CA+MTA’ 
group; in model 2, any individual who had missing values 
for CeVD and atrophy severity was assigned to ‘none-mild 
CeVD and no atrophy’ group. All analyses were controlled 
for covariates such as age, education, gender, CI status, 
presence of hypertension, hyperlipidemia, diabetes, 
ischaemic heart disease, smoking history and history 
of stroke. All analyses were performed using standard 
statistical software (Statistical Package for Social Science 
(SPSS) V.24; SPSS, Inc.) and a p value of<0.05 (two-sided) 
was used to indicate significance. Bonferroni correction 
was performed to obtain adjusted significance level for 
individual domain-specific cognitive test: ≈0.05/7≈0.007.
resulTs
Out of the 911 participants recruited into the study, 92 did 
not complete MRI scans or had MRI scans that could not 
be graded, leaving a total of 819 participants included in 
this analysis. There was no significant difference between 
participants who were included in and excluded from the 
analysis. Table 1 shows the characteristics of study partic-
ipants.
A total of 520 participants had none-mild CeVD burden, 
among whom 362 (69.6%) had neither significant CA 
nor MTA, 133 (25.6%) had CA only and 25 (4.8%) 
had CA+MTA. Out of the 299 participants with moder-
ate-severe burden of CeVD, there was more atrophy: 
109 (36.5%) had neither significant CA nor MTA, 132 
(44.1%) had CA and 58 (19.4%) had CA+MTA (χ2=96.4, 
p<0.001). There were no subjects with MTA alone.
In the whole sample, there was a significant difference 
in the global cognitive z-score across the three atrophy 
groups (0.26±0.87, –0.08±0.82 and −0.51±0.77, respec-
tively, p<0.001), after controlling for age, gender, educa-
tion, CI status and the presence of vascular risk factors.
Additive effect of CeVd and atrophy
Further Analysis of Variance (ANOVA) models were 
conducted, which showed that in the none-mild CeVD 
group, there was no significant difference in scores 
between all three atrophy groups in global cognition. 
In subjects with significant CeVD, the CA+MTA group 
performed significantly worse than the no atrophy group 
(mean difference=−0.46, 95% CI −0.74 to −0.19, p<0.001) 
and CA group (mean difference=−0.35, 95% CI −0.60 
to −0.11, p=0.002) (figure 1), after controlling for age, 
gender, education, CI status and the presence of vascular 
risk factors.
In domain-specific cognitive performance, there was 
no significant difference between atrophy groups in 
subjects with none-mild levels of CeVD. However, in the 
moderate-severe CeVD group, subjects with CA+MTA 
had worse deficits in executive function (p=0.001), visual 
memory (p=0.005) and visuomotor speed (p<0.001) 
domains compared with those with no atrophy or CA only 
(table 2).
Notably, there was no significant difference in the global 
cognitive z-score for non-significant and significant CeVD 
groups among subjects with CA+MTA (F(82)=0.80, p=0.37), 
after controlling for covariates. This reflects a unidirec-
tional additive effect of atrophy (CA+MTA) on top of 
CeVD, but not vice versa.
sensitivity analysis
Missing data were imputed in two models. In model 1, 
all subjects with missing MRI data were assigned with 
moderate-severe CeVD and CA+MTA. ANOVA conducted 
showed that in subjects with none-mild CeVD, the 
CA+MTA group performed significantly worse than the 
no atrophy group (mean difference=−0.32, 95% CI −0.65 
to −0.003, p=0.04). In subjects with moderate-severe 
CeVD, there was no significant difference across the three 
atrophy groups.
In model 2, all subjects with missing MRI data were 
assigned with none-mild CeVD and no atrophy. ANOVA 
analysis showed that while no significant difference across 
atrophy groups was seen in none-mild CeVD group, 
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Table 1 Characteristics of the study population
No atrophy
(n=471)
CA
(n=265)
CA+MTA
(n=83) P value
Age, mean±SD 67.7±5.5 72.2±6.1 74.9±6.5 <0.001
Education 0.019
  ≤6 years, n (%) 278 (59.0) 177 (66.8) 60 (72.3)
Gender <0.001
  Female, n (%) 274 (58.2) 127 (47.9) 25 (30.1)
Race 0.045
  Chinese, n (%) 157 (33.3) 85 (32.1) 34 (41.0)
  Malay, n (%) 155 (32.9) 84 (31.7) 34 (41.0)
  Indian, n (%) 159 (33.8) 96 (36.2) 15 (18.1)
Hypertension, n (%) 354 (75.2) 229 (86.4) 76 (91.6) <0.001
Hyperlipidemia, n (%) 356 (75.6) 198 (74.7) 61 (73.5) NS
Diabetes mellitus, n (%) 154 (32.7) 113 (42.6) 37 (44.6) 0.009
History of stroke, n (%) 10 (2.1) 22 (8.3) 10 (12.0) <0.001
Ischaemic heart disease, n (%) 26 (5.5) 26 (9.8) 8 (9.6) NS
Smoking history, n (%) 108 (22.9) 78 (29.4) 35 (42.2) 0.001
CI status, n (%) <0.001
  NCI 175 (37.2) 68 (25.6) 10 (12.0)
  CIND mild 171 (36.3) 85 (32.1) 19 (22.9)
  CIND moderate 125 (26.5) 112 (42.3) 54 (65.1)
CA+MTA, cortical atrophy and medial temporal atrophy; CI, cognitive impairment; CIND, cognitive impairment-no dementia; NCI, no cognitive 
impairment; NS, not significant.
Figure 1 Global cognitive z-score in different atrophy 
groups stratified by CeVD burden severity. Values are mean 
(SE). No atrophy, defined by the absence of significant 
atrophy (CA and MTA); CA, defined by the presence of 
significant CA and the absence of MTA; CA+MTA, defined by 
the presence of significant CA and MTA. CA, cortical atrophy; 
CeVD, cerebrovascular disease; MTA, medial temporal 
atrophy.
CA+MTA groups demonstrated more significant global 
cognitive deficit than those with no atrophy (mean differ-
ence=−0.46, 95% CI −0.74 to −0.19, p<0.001) and those 
with CA only (mean difference=−0.35, 95% CI −0.60 to 
−0.11, p=0.002).
dIsCussIOn
The main finding of the current study is that in an elderly 
dementia-free population in Asia, among subjects with 
none-mild CeVD burden, the presence of CA and MTA 
did not show significant adverse effect on cognitive func-
tion, while in those with a moderate-severe level of CeVD 
burden, the presence of significant CA+MTA further 
worsened global cognitive function compared with those 
with CA only, with predominant impairment in specific 
cognitive domains such as visual memory, executive func-
tion and visuomotor speed.
With the growing awareness of the coexistence of 
AD pathology and CeVD, there have been reports that 
dementia patients with signs of CeVD also have a concom-
itant neurodegenerative disease and that dementia 
patients with dual pathologies have more impaired 
cognitive functions compared with those with purely AD 
pathology.25 26 To complement previous studies, we report 
that even in a dementia-free population, subjects with 
both CeVD and atrophy, especially atrophy in multiple 
brain regions, demonstrated further reduction in cogni-
tive function, reflecting the additive effects of both neuro-
degenerative processes and CeVD.
Previously, decreased MTA volume was found to be 
associated with poor memory performance with a partic-
ular effect on visual memory.27 However CA was not taken 
into consideration in the study; hence, its role in affecting 
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Table 2 Domain-specific cognitive z-scores in no atrophy, CA and CA+MTA groups in different CeVD groups
Groups 
Cognitive scores
None-mild CeVD Moderate-severe CeVD
P
(for trend)
No atrophy 
(n=362) CA (n=133)
CA+MTA 
(n=25)
No atrophy 
(n=109) CA (n=132)
CA+MTA 
(n=58)
Executive function 0.27
(0.18, 0.36)
0.23
(0.10, 0.37)
−0.21
(−0.53,0.11)
0.19
(0.03, 0.34)*
0.07
(−0.10, 0.23)†
−0.33
(−0.64,–0.02)*† 
0.002
Attention 0.28
(0.19, 0.36)
0.22
(0.08, 0.36)
−0.04
(−0.37, 0.28)
0.16
(0.01, 0.32)
−0.20
(−0.37,–0.03)
−0.35
(−0.66,–0.04)
0.001
Language 0.28
(0.19, 0.36)
0.22
(0.08, 0.36)
−0.04
(−0.37, 0.28)
0.16
(0.01, 0.32)
−0.20
(−0.37,–0.04)
−0.35
(−0.66,–0.04)
<0.001
Verbal memory 0.35
(0.26, 0.44)
0.23
(0.09, 0.38)
−0.19
(−0.52, 0.14)
0.08
(−0.08, 0.24)
0.01
(−0.16, 0.18)
−0.25
(−0.56,0.07)
<0.001
Visual memory 0.33
(0.25, 0.41)
0.27
(0.14, 0.40)
−0.23
(−0.53, 0.07)
0.19
(0.04, 0.33)*
−0.12
(−0.27, 0.03)
−0.39
(−0.67,–0.11)*
<0.001
Visuoconstruction 0.30
(0.21, 0.38)
0.24
(0.10, 0.38)
−0.30
(−0.63, 0.02)
0.09
(−0.06, 0.25)
0.04
(−0.12, 0.21)
−0.09
(−0.39, 0.22)
0.002
Visuomotor speed 0.31
(0.23, 0.39)
0.18
(0.05, 0.30)
−0.29
(−0.57, 0.003)
0.11
(−0.03, 0.24)*
0.09
(−0.05, 0.24)† 
−0.22
(−0.49, 0.06)† 
<0.001
Values are adjusted means (95% CI). CeVD, Cerebrovascular Disease. The model controlled for age, education, gender and cognitive 
impairment status. 
*Significant difference between no atrophy and CA+MTA groups.
†Significant difference between CA and CA+MTA groups.
cognition, especially visual memory function, was not 
investigated. In the present study, the addition of MTA 
to CA further worsened the visual memory function. This 
suggests that MTA contributes significantly to dysfunction 
visual memory not only independently, but also additively 
to the presence of significant CA. However, this additive 
effect was only seen in subjects with significant CeVD 
and not in those with mild or no CeVD. The threshold 
effect of CeVD on visual memory has been previously 
reported,13 highlighting the importance of investigating 
CeVD markers in addition to markers of neurodegenera-
tion. Our results provide further emphasis on the crucial 
need of investigating the cumulative and synergistic 
effect of brain structural abnormalities on neurocognitive 
function.
While it is believed that CeVD could result in disrup-
tions of cortico–cortico connections leading to impaired 
executive function and reduced processing speed, 
some studies suggest that these lesions may potentially 
exacerbate CA.28 Animal studies have suggested that 
vascular dsyfunction may trigger amyloid production 
through increased oxidative stress or neuroinflamma-
tive responses.29 However, the underlying mechanism in 
the interaction between CeVD and neurodegeneration 
remains inconclusive and further prospective neuro-
pathological studies are required to elucidate the direc-
tional associations between vascular and AD pathologies.
The present study has weaknesses and strengths. The 
main limitation is that only screen-positive subjects in 
phase I were included in phase II of the study. As has 
been stated previously, subjects who refused to partic-
ipate in phase II were older, had lower education and 
socioeconomic status, higher blood pressures and lower 
cholesterol levels.16 This may have led to an underesti-
mation of the prevalence of CeVD in the present study.13 
It also affects the generalizability of study results to the 
whole study population; however, sensitivity analyses 
showed that the primary results were robust. In addition, 
there is no subject with only MTA but not CA. This disal-
lows comparison between the two different patterns of 
atrophy. Other limitations of this study include the lack 
of control for possible medications or treatments taken 
by the subjects and the lack of other supportive AD 
biomarkers such as amyloid burden. The main strengths 
of our study include the large sample size, a communi-
ty-based study population and the inclusion of multiple 
CeVD markers which provided an integrated measure-
ment of global brain structural abnormalities. A further 
strength was the use of a comprehensive neuropsycholog-
ical battery, which was able to generate both global and 
domain-specific cognitive indexes.
COnClusIOns
We found that the presence of atrophy, especially MTA, in 
addition to moderate-severe global CeVD burden further 
worsens cognitive dysfunction in a dementia-free elderly 
population. Our findings suggest that there is a threshold 
effect of CeVD burden at which the neurodegenerative 
disease begins to demonstrate significant additive effect, 
even at preclinical stages of dementia. Further studies in 
other populations are needed to replicate these findings 
and to investigate the mechanisms for this clinico-patho-
logical interaction.
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